Pharma Journalist

6th Oligonucleotides for CNS Summit
2026-08-19 - 2026-08-21 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 6th Annual Oligonucleotides for CNS Summit USA returns to Boston on 19–21 August 2026, uniting 160+ leaders across pharma and biotech to accelerate the discovery, translation and clinical success of CNS‑targeted oligonucleotide therapies. As advances in RNA chemistry, delivery technologies and clinical evidence unlock previously undruggable CNS targets, this meeting is the industry’s most focused forum to benchmark what is truly working — and what’s next.
Across three highly interactive days, hear the latest data and strategy from companies including Eli Lilly, Stoke Therapeutics, Dyne Therapeutics, Creyon Bio and Quiver Bioscience, covering ASOs, siRNAs, saRNAs and aptamers. Dive into real‑world challenges around CNS penetration, BBB shuttles, intrathecal vs systemic delivery, splice modulation, chemistry and conjugation design, PK/PD translation, safety and regulatory alignment — all through case studies, panels, workshops and roundtables designed for open, precompetitive discussion.
With expanding pipelines, growing competition and rising expectations for clinical impact beyond rare disease, this summit offers a uniquely concentrated environment to learn from clinical‑stage programs, stress‑test your development strategy and connect with the scientists and decision‑makers shaping the future of CNS oligonucleotides.
Find out more today – https://ter.li/twgv2av6

6th iPSC Drug Development Summit
2026-09-09 - 2026-09-10 | Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA, 02128, United States
As iPSC therapies transition from promise to clinical reality, the 6th iPSC Drug Development Summit arrives at a pivotal moment for biopharma leaders advancing next-generation cell therapies. Bringing together senior scientists, CMC experts, and decision-makers, this industry-focused meeting is dedicated exclusively to accelerating iPSC-based drug development from discovery through clinical translation and commercialization.
This year’s agenda is designed to address the most pressing challenges across the iPSC pipeline, with a sharp focus on scalability, manufacturability, and regulatory alignment as therapies move toward late-stage clinical success. Attendees will gain practical insights across two core tracks, covering preclinical development and process development & CMC, including genome editing strategies, donor and cell line selection, functional quality control, and GMP-ready manufacturing approaches.
The summit features 25+ expert speakers from leading organizations actively advancing iPSC therapies across indications such as Parkinson’s disease, diabetes, oncology, and ocular disorders.
Speaker highlights include:

Yanzheng Liu, Senior Director, Aspen Neuroscience
Rachel Knopp and Yongting Wang, Astellas Pharma
William Hendriks, Director of PSC Biology, BlueRock Therapeutics
Eric Law, Head of CMC Regulatory Affairs, Century Therapeutics
Alex Ng, Chief Scientific Officer, GC Therapeutics
Marcella Garita-Hernandez, Head of iPS Core, Harvard Medical School

With contributions from organizations including Astellas Pharma, BlueRock Therapeutics, Aspen Neuroscience, Vertex Pharmaceuticals, and more, the meeting provides a unique opportunity to learn directly from teams generating clinical data and overcoming real-world development bottlenecks.
Designed for professionals actively building iPSC pipelines, the summit offers an end-to-end view of the field, alongside collaborative networking with peers across biopharma, academia, and investment. From optimizing early discovery decisions to ensuring commercial readiness, this is the must-attend forum to benchmark strategies and accelerate the path to clinically successful iPSC therapies.
Find out more here: https://ter.li/japojzin
This meeting is free to attend* for biopharma and academics.

9th Neuropsychiatric Drug Development Summit
2026-09-15 - 2026-09-17 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The Neuropsychiatric Drug Development Summit is the definitive meeting for biopharma leaders shaping the future of psychiatric R&D. At a time of renewed momentum in neuropsychiatry, this summit brings together senior decision‑makers to redefine how the industry translates science into successful, patient‑centred therapies.
Across discovery, translational science, and clinical development, the agenda showcases the most promising advances in the field — from psychedelics, muscarinics, orexins, and novel neuroplasticity approaches to cutting‑edge translational tools such as EEG, digital and speech biomarkers, sleep endpoints, and smarter patient stratification. Attendees will gain practical insights into overcoming placebo response, heterogeneity, and late‑stage failure through biology‑driven, regulatory‑ready strategies.
Designed for meaningful connection and collaboration, the summit offers an intimate, highly interactive environment to exchange data, challenge assumptions, and build partnerships with peers tackling depression, schizophrenia, bipolar disorder, anxiety, PTSD, and addiction. Join the global community accelerating the next era of precision psychiatry.
Find out more today – https://ter.li/rt2cakk3

COPD Drug Development Summit
2026-09-15 - 2026-09-17 | Homewood Suites by Hilton Boston Seaport District, 670 Summer Street, Boston, MA, 02210, United States
The First Industry‑Led Meeting Dedicated to Advancing Next‑Generation COPD Therapeutics
The COPD Drug Development Summit is the first and only industry‑driven forum designed to accelerate meaningful innovation in chronic obstructive pulmonary disease.
With the approval of the first biologic therapy marking a historic turning point, COPD R&D is entering a new era, one defined by deeper biological understanding, more precise patient segmentation, and a renewed push toward disease‑modifying treatments.
This summit convenes leading scientists, clinicians, regulatory experts, and biotech innovators to address the scientific and operational barriers that have long constrained progress.
Over three days, attendees will explore the most urgent and promising areas shaping the future of COPD therapeutics.
Core themes include novel target discovery, translational alignment, and smarter clinical trial design that reflects the heterogeneity of COPD endotypes.
The program also examines the limitations of traditional endpoints such as exacerbations and FEV₁, highlighting next‑generation measures, including imaging‑based progression tools, AI‑enabled assessment, and biomarkers capable of capturing early disease activity and therapeutic impact.
With 65+ industry leaders and 16+ expert speakers from organisations including Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Generate Biomedicines, and Ethris, the summit offers a uniquely concentrated environment for scientific exchange and partnership building.
Participants will engage in 7+ hours of structured networking, panel discussions, and case‑study‑driven sessions that illuminate both the opportunities and the remaining challenges in COPD drug development.
Designed for discovery scientists, translational researchers, clinical developers, regulatory strategists, and biotech executives, this event provides a rare chance to shape the next chapter of COPD innovation.
As the field moves toward more personalised, mechanism‑driven approaches, the COPD Drug Development Summit serves as a critical platform for aligning science, strategy, and regulatory confidence to deliver better outcomes for millions of patients worldwide.
Register now: https://ter.li/kvevwxqk

11th CAR-TCR Summit
2026-09-15 - 2026-09-17 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
All eyes are on the next wave of CAR and TCR innovation. Success is no longer defined by clinical wins alone, but by smarter biological design, delivery strategies and manufacturing breakthroughs to lower COGs, expand patient access and secure commercial viability.
With this, the 11th CAR-TCR Summit is making its hotly anticipated return to Boston, September 15-17.
View the agenda here.
Crafted in collaboration with industry veterans and spanning four tracks across the entire development life cycle, the program offers a clear, strategic view of the next era of cell therapy. Expect first hand insight into cutting-edge in vivo and next generation CAR and TCR innovations, hear unpublished clinical data across emerging indications, and learn from real world automated manufacturing case studies shaping commercial readiness.
Beyond the science, you’ll gain direct access to investors to align on where capital and strategic partnerships are moving next, complemented by high-value networking with C-suite executives and academic KOLs to safegaurd every stage of your cell therapy development pipeline.
If you’re committed to driving the innovation and commercial readiness needed to make CAR-T therapies safer, more effective, scalable, and accessible to the patients who need them most, then this is the meeting for you.
Download your copy of the agenda.

Measuring Patient Engagement Summit Europe
2026-09-15 - 2026-09-17 | Hilton London Kensington, 179-199 Holland Park Ave, London, W11 4UL, United Kingdom
The Measuring Patient Engagement Summit Europe is the leading industry forum dedicated to supporting biopharma in quantifying and demonstrating the true impact of patient engagement. As regulatory expectations rise and internal stakeholders demand a clearer return on investment, the need for robust, evidence-based frameworks has never been greater. This three-day summit brings together over 70 senior leaders across patient engagement, advocacy, insights, experience, and medical affairs to address one of the industry’s most pressing challenges – moving from activity-based reporting to measurable impact and defensible KPIs.
Designed to bridge the gap between strategy and proof, the event focuses on establishing credible, comparable, and actionable metrics that demonstrate how patient engagement influences decision-making across the product lifecycle. Attendees will gain practical insights into how patient input drives improvements in protocol design, accelerates clinical trial recruitment, supports regulatory alignment, and strengthens market access outcomes.
Through a combination of real-world case studies, expert-led discussions, and collaborative sessions, the summit offers a unique opportunity to benchmark approaches, co-develop frameworks, and create a shared language of value recognised by regulators, payers, and patients alike. By equipping participants with proven methodologies and peer-tested tools, the event empowers organisations to embed patient engagement as a strategic, data-driven driver of innovation – ensuring its impact is both defensible and impossible to ignore.
Agenda Highlights Include:

Moving beyond activity-based KPIs to define and measure meaningful patient engagement impact
Demonstrating measurable outcomes across clinical trial design, recruitment, and retention
Quantifying the influence of patient insights on regulatory, payer, and market access decisions
Developing credible and standardised frameworks to benchmark engagement success
Translating patient experience data into tangible clinical and commercial value
Aligning patient engagement strategies with ESG and broader organisational priorities
Building a common language of value recognised across industry stakeholders

This summit provides a critical platform for advancing the measurement of patient engagement, enabling organisations to shift from intention to evidence and truly demonstrate the value of patient-centric approaches.
Get your copy of the agenda now to learn more: https://ter.li/fy580o27.

4th TRP Supply Chain & Manufacturing Summit
2026-09-15 - 2026-09-17 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
4th TRP Supply Chain & Manufacturing Summit (September 15–17, 2026 | Boston, MA)
Radiopharmaceuticals are entering a defining stage of development. As clinical programs advance into Phase II, Phase III, and commercial readiness, the ability to manufacture and deliver therapies reliably has become one of the industry’s greatest challenges. Rising demand for isotopes, infrastructure constraints, workforce shortages, evolving regulatory expectations, and the unique realities of short half-life materials are placing unprecedented pressure on supply chain and manufacturing teams.
The 4th TRP Supply Chain & Manufacturing Summit is the only industry-focused forum dedicated exclusively to the supply chain, manufacturing, CMC, quality, and logistics challenges impacting radiopharmaceutical development. Bringing together 60+ senior leaders from pharma, biotech, CDMOs, isotope providers, and logistics organizations, the meeting is designed to help attendees overcome the operational bottlenecks that stand between scientific breakthroughs and patient delivery.
Across two conference days and interactive workshops, attendees will gain practical insights to:

Strengthen isotope supply resilience across established and emerging alpha and beta emitters
Scale manufacturing operations to support late-stage clinical trials and commercialization
Evaluate build vs. buy manufacturing strategies and optimize CDMO partnerships
Implement automation and digital solutions to improve consistency, throughput, and compliance
Optimize logistics and distribution networks for time-sensitive radiopharmaceutical therapies
Navigate evolving regulatory expectations with greater confidence and preparedness

Featuring experts from AstraZeneca, Bayer, Telix Pharmaceuticals, Cellectar Biosciences, Ratio Therapeutics, Convergent Therapeutics, Molecular Partners AG, Purdue University, and the University of Alabama at Birmingham, the summit delivers real-world case studies and practical strategies from organizations actively addressing today’s most pressing supply chain and manufacturing challenges.
With 10+ hours of dedicated networking, attendees can benchmark approaches, exchange lessons learned, and build the partnerships needed to move radiopharmaceutical therapies from bench to patient reliably and at scale.

5th Lipid Nanoparticles Development Summit Europe
2026-09-23 - 2026-09-24 | Dorint Kurfürstendamm Berlin, Augsburger Strasse 41, Berlin, 10789, Germany
The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin, 23rd – 24th September 2026, as the leading meeting for advancing LNP-enabled gene therapy delivery. Bringing together experts from BioNTech, AstraZeneca, Johnson & Johnson, Sanofi and AbbVie, the summit covers end-to-end LNP development, from formulation through to analytics, CMC and scalable manufacturing. Attendees will explore solutions to overcome liver tropism, enable extrahepatic delivery and engineer next-generation nanoparticle systems across mRNA, DNA and gene editing therapies. With interactive discussions and real-world case studies, this event delivers actionable insights to accelerate safe, targeted and clinically viable delivery platforms.
To learn more and register online, please visit: https://ter.li/mft1fbw0

7th Genome Editing Therapeutics Summit
2026-09-28 - 2026-09-30 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The FDA has shown its’ hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options.

But intent and support alone won’t get these therapies to patients. Developmental, manufacturing, and regulatory challenges still stand between the lab and the patients waiting.
That’s why the 7th Genome Editing Therapeutics Summit is returning to Boston this September, as the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting.
Join R&D, preclinical, translational, regulatory, and c-suite leaders to answer one question: how do we maximize the application of genome editing therapies to patients who need them most?
Don’t miss out on insights from AbbVie, Bristol Myers Squibb, Intellia Therapeutics, Beam Therapeutics, Sanofi, and many more on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.
What’s New in 2026?
In 2026, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA’s new mechanism pathway reshaping strategy, the decisions made now will determine which assets reach patients.
At this year’s summit you will:

Delve into extrahepatic delivery strategies to widen your technology across multiple disease indications

Learn from clinical companies building robust IND packages to fast-track development

Evaluate immunogenicity and off-targeting case studies to sharpen your therapy’s safety profile

Explore the Brand-New Agenda to Discover:

3 days of content to find the sessions your program needs most

50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage

80% Directors, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers

64% in vivo & 36% ex vivo agenda to fit your route of delivery

2 brand-new workshops

View the full program here to see the 18+ speaker faculty and full session details: https://ter.li/sda9n7qy

10th IPF Summit
2026-09-29 - 2026-10-01 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
10th Anniversary Edition of the IPF Summit –
September 29 – October 1, 2026 | Boston, MA
For a decade, the IPF Summit has been the go-to, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year, the stakes, and the opportunity, have never been higher.
Following a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb, United Therapeutics, and Boehringer Ingelheim, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge, the question is no longer can we develop treatments, but how to do so smarter, faster, and with meaningful differentiation.
The 10th IPF Summit is the only end-to-end, industry-led meeting designed to tackle this challenge head-on.
Bringing together 150+ experts across discovery, translational science, and clinical development, from organizations including Bristol Myers Squibb, United Therapeutics, Boehringer Ingelheim, Pfizer, Novartis, AbbVie, PureTech Health, Insilico Medicine, and many more, the summit offers a uniquely integrated view of the scientific, clinical, and strategic decisions shaping the next decade of IPF innovation.
Across dedicated content tracks, dive into emerging biology and novel targets to unlock new therapeutic avenues, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape
New for 2026 includes a dedicated ILD & PPF Focus Day, designed to unpack the complexity of fibrotic lung diseases beyond IPF, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.
With 8+ hours of networking in an intentionally intimate setting, the summit is built for honest, high-value discussions, giving you direct access to the people shaping the future of pulmonary fibrosis drug development.
Whether you’re advancing early discovery, translating assets into the clinic, or positioning therapies in a crowded market, this is where the field aligns on what success now looks like, and how to achieve it.
Find out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk

Designing the AI-Enabled Life Sciences Workforce Summit Europe
2026-09-29 - 2026-09-30 | Essential by Dorint Basel City, Schönaustrasse 10, Switzerland, Basel, 4058, Switzerland
AI is no longer a future concept in life sciences – it is actively reshaping how work gets done, how decisions are made, and how value is created. Yet most organisations are still navigating how to move from ambition to enterprise-wide execution.
The Designing the AI-Enabled Life Sciences Workforce Summit Europe is the only forum built specifically for senior HR leaders to tackle this challenge head-on. Bringing together CHROs and workforce transformation leaders from leading drug developers, this is where strategy meets execution – and where organisations learn how to redesign work, skills, and operating models to deliver measurable business impact at scale.
At a time when life science organisations must drive productivity, innovation, and growth without increasing headcount, this event provides the practical frameworks, peer insights, and proven strategies you need to move faster with confidence.
This is not a conference about AI trends – it is a working forum focused on how life sciences organisations are redesigning work, workforce strategy, and operating models in response to AI.
Across two highly interactive days, you will learn directly from leaders who are actively transforming their organisations – moving beyond pilots to deliver enterprise-wide impact. Through a unique blend of case studies, discussion, and working sessions, you will leave not only inspired but equipped with clear, actionable next steps.
For more information and to register online, please click here.

5th mRNA Process Development & CMC Summit 2026
2026-09-29 - 2026-10-01 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The mRNA Process Development & CMC Summit returns for its 5th Anniversary, bringing together the brightest minds in mRNA development, manufacturing, and CMC strategy.
As the field continues to evolve at pace, this milestone edition is your opportunity to connect, learn, and stay ahead of the curve with the leaders shaping the future of mRNA therapeutics, including senior decision-makers from GSK, Eli Lilly, Centivax, Circurna, Sanofi, BioNTech and more!
From scaling processes and strengthening analytical capabilities to navigating global expansion and clinical readiness, this is where the industry’s most pressing CMC challenges are tackled head-on.
Find out more: https://ter.li/peoi4f1e

16th World Clinical Biomarkers & Companion Diagnostics Summit
2026-10-05 - 2026-10-08 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Fueled by surging digital pathology partnerships, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs, the precision medicine field is evolving rapidly.
Building on this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall, uniting 850+ senior stakeholders in the common goal of advancing timely, accessible and affordable precision medicine to patients in need.
Be the first to access our new event program: https://ter.li/5c0adwgh
Join industry-leading peers from biopharma, diagnostics, testing labs, and regulatory bodies, to unpack fit-for-purpose CDx strategies, spark new co-development partnerships, discover cutting-edge genomic sequencing, pathology, multi-omic, single cell and multimodal innovations.
This year’s agenda will expand to five dedicated tracks of content to ensure your entire team leave equipped with the tools and insights to tackle the specific challenges facing them at their stage of development.

Biomarker Discovery & Translation
Clinical & CDx Development
Rx-Dx Commercialization & Adoption
Digital Pathology & Spatial Biomarkers (BRAND-NEW)
Multimodal & AI‑Enabled Endpoints (BRAND-NEW)

Grasp the opportunity to attend the industry’s leading touchpoint for drug-diagnostic co-development advancement.
Together let’s translate promising precision medicine into scalable, equitable drug-diagnostic therapies for patients across oncology, neurological, autoimmune, rare and chronic diseases.
Sign up today: https://ter.li/0jb66uvu
Registration is FREE* for drug developers and researchers.
*Subject to terms and conditions visit the website to learn more.

17th World ADC San Diego
2026-10-12 - 2026-10-15 | Town & Country San Diego, 500 Hotel Circle, North San Diego, San Diego, CA, 92108, United States
Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes.
With 7 streams of end-to-end ADC content across Discovery Chemistry, Discovery Biology, Preclinical, Translational Medicine, Clinical Lessons, Process & Analytical Development, and Manufacturing & Supply, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments.
Uniting 1,300 industry senior enthusiasts from biopharma, innovative start-ups, leading service providers and academic, physician and regulator KOLs, World ADC San Diego is the place to discuss, debate and advance the future of ADC development.
Featuring 170+ senior presenters, a snapshot of the 2026 speaker faculty includes:

Suzanne Edavettal, Vice President, Research & Head, Protein Therapeutics, Amgen
Vinod Bulusu, Executive Director, Product Stewardship Lead, AstraZeneca
Giorgia Vicentini, Vice President, Global Program Lead, Oncology, Bristol Myers Squibb
Ronald Fleming, Executive Director, Clinical Development, Daiichi Sankyo
Gail Lewis, Distinguished Scientist, Discovery Oncology, Genentech
Min Hu, Senior Vice President, Discovery, Innovent Biologics
Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics
Jeffrey Settleman, Chief Scientific Officer, Oncology R&D, Pfizer
Dominik Schumacher, Chief Executive Officer, Tubulis
Rita Nanda, Associate Professor, Medicine & Director, Breast Oncology, Section of Hematology/Oncology, University of Chicago

View the full list of speaking companies: https://ter.li/xsz013cs
If you want to stay competitive in the field, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.

5th Operationalise: Early Access Programmes Summit Europe
2026-10-19 - 2026-10-21 | Park Plaza Victoria London, 239 Vauxhall Bridge Road Pimlico, London, SW1V 1EQ, United Kingdom
Early Access Programmes have evolved into a critical, but increasingly complex, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines, evidence generation, and patient access across global markets.
The 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning that strategy into execution. As regulatory expectations shift, reimbursement timelines extend, and programmes scale globally, organisations must make more decisions, earlier, and with greater consequence.
This is the only European forum dedicated to the operational reality of early access – bringing together 140+ leaders across Medical Affairs, Access, Regulatory, Clinical Operations, and Supply to share how programmes are being designed, adapted, and delivered in practice.
Whether you are building your first programme, scaling across regions, or managing a global access portfolio, this is your opportunity to benchmark your approach, challenge your assumptions, and leave with the insight needed to make smarter decisions and deliver earlier, sustainable access for patients in 2026 and beyond.
For more information and to register online, please click here.

4th Covalent Drug Discovery & Development Summit
2026-10-20 - 2026-10-22 | Hampton Inn Boston Seaport District, 670 Summer St, Boston, MA, 02210, United States
4th Covalent Drug Discovery & Development Summit (October 20–22, Boston, MA)
Covalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns, advances in chemistry, screening technologies, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology.
As the field evolves, the challenge is no longer proving potential. The priority is successful clinical translation. From predicting off-target toxicity to optimizing PK/PD and dose selection, teams continue to face uncertainty when moving from discovery into the clinic. Many programs still encounter critical gaps in translating promising preclinical data into patient outcomes.
The 4th Covalent Drug Discovery & Development Summit is the only industry-led forum dedicated to bridging discovery through to clinical application. Designed to unite medicinal chemists, chemical biologists, translational scientists, and early clinical leaders, the meeting delivers a truly end-to-end perspective across covalent drug development, now with expanded clinical content reflecting the growing pipeline of first-in-human and Phase II programs.
Across two conference days and interactive workshops, attendees will gain practical, actionable insights to:

Design safer, more selective covalent compounds using novel warheads and structure-guided approaches
De-risk development through advanced toxicity, reactivity, and safety assessment strategies
Integrate translational data to improve in vitro to in vivo correlation and support confident clinical decisions
Expand the druggable space by targeting new residues and previously undruggable biology

With case studies spanning AI-driven discovery, chemoproteomics, kinetic assays, and translational workflows, the summit showcases how the field is moving beyond traditional targets and into next-generation covalent therapies.
Bringing together 80+ senior leaders from pharma, biotech, and academia, this is a highly curated environment for deep technical exchange, collaboration, and real-world problem solving.
Whether you are optimizing discovery, scaling translational strategy, or preparing for the clinic, this is the critical forum to understand what it truly takes to move covalent therapies from concept to clinic and to help shape the next wave of precision medicines.

9th TPD & Induced Proximity Summit
2026-10-26 - 2026-10-29 | The Omni Boston Hotel at the Seaport, 450 Summer Street, Boston, MA, 02210, United States
After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone.
However, following the risk-averse funding environment of 2025, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development, it is designed to help you discover the best novel targets, optimize your degrader profile, and accelerate your pipelines to the clinic and beyond.
View the full event guide.

3rd Raw Materials for Cell & Gene Therapy Summit
2026-10-26 - 2026-10-28 | The Westgate Hotel, 1055 2nd Ave, San Diego, CA, 92101, United States
Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk.
Following the sunshine to San Diego, the 3rd Raw Materials for Cell & Gene Therapy Summit is the only dedicated forum designed to help you take control of this risk. Through technical case studies and cross-functional discussion, you will uncover practical, phase-appropriate strategies to manage variability, strengthen supplier qualification, and build raw material frameworks that scale confidently from early development through to commercial manufacturing.
By joining leading experts across quality, MSAT, supply chain, and process development, you will engage in face-to-face discussions on how peers are defining material specifications, managing lot-to-lot variability, and making critical qualification decisions under real development pressure.
Move on from theory and step inside the conversations shaping how raw material strategies are implemented in practice. Across technical case studies, peer-led discussions, and interactive workshops, you’ll explore how teams are managing suppliers, qualifying materials, overseeing supply chains, and navigating regulatory uncertainty in real-world settings.
Explore the 2026 Agenda to Discover:

19+ cross-functional experts spanning quality, MSAT, and supply chain shaping raw material strategies
2 in-depth workshops to deep dive into particulate risk and material transitions before they delay your programme
Dedicated networking sessions & interactive roundtables designed to spark meaningful, problem-solving conversations
Face-to-face access to peers and decision-makers to exchange practical experiences not captured in published reports

View the full program here to see the 19+ speaker faculty and full session details: https://ter.li/e0a0ldog

14th IMPACCT Real-World Evidence Summit
2026-10-27 - 2026-10-28 | Courtyard Boston Marriott Downtown, 275 Tremont St, Boston, MA, 02116, United States
The 14th IMPACCT Real-World Evidence Summit is the only dedicated industry forum uniting leaders across RWE, real-world data, evidence generation, HEOR, and market access to tackle the most pressing challenges in the field. From selecting regulatory-ready datasets to embedding AI and advanced analytics into workflows, this summit focuses on how to consistently translate data into actionable decisions.
Join leading experts from AstraZeneca, Pfizer, Novartis, Boehringer Ingelheim and more to build integrated evidence strategies, accelerate timelines, and maximize the ROI of real-world evidence investment.
To more know more visit https://ter.li/m55b0flb

2nd Obesity & Weight Loss Drug Development Summit Europe
2026-10-28 - 2026-10-29 | Hyperion Hotel Munich, Truderinger Strasse 13, Munich, 81677, Germany
GLP-1s changed the treatment paradigm for obesity reaching new heights of efficacy. Now, as unmet need persists and the field looks beyond efficacy alone, momentum is building behind therapies that can deliver lasting weight management through improved tolerability, muscle preservation, personalised treatment approaches, and more convenient administration.
As obesity investment and pipeline activity surge across Europe, the 2nd Obesity & Weight Loss Drug Development Summit Europe is a unique opportunity to engage with the region’s leading innovators and emerging stakeholders, advancing the next wave of obesity therapeutics beyond first-generation GLP-1s.
Unlike broad academic meetings, this industry-centred forum goes beyond data headlines to explore new MoA, combination therapies, tolerability improvements and critical lessons to define the 2nd generation of obesity and weight loss therapeutics and strengthen Europe’s footprint in this increasingly competitive global landscape
Join us to shape the next era of obesity care.
View the full event guide: https://ter.li/p453jn

10th Dermatology Drug Development Summit
2026-11-03 - 2026-11-23 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
10th Dermatology Drug Development Summit – Discovering, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5, 2026 | Boston, MA
The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease.
Marking a decade of convening the field’s most influential voices, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis, developers are under growing pressure to demonstrate meaningful differentiation, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies.
Designed as an intimate, discussion-led forum, the summit brings together more than 90 experts spanning discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions.
The meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets, and share practical lessons from across the dermatology pipeline.
Attendees will hear from 40+ senior leaders representing major pharmaceutical companies, innovative biotechs, academic research centers, and patient advocacy organizations, with representation from AbbVie, Galderma, Merck, SUN Pharma, Eli Lilly, UNION Therapeutics and others.
This year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial.
New additions include a Pre-Conference Workshop Day, offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa, exploring strategies to drive earlier intervention and disease modification, and rare & ultra-rare inflammatory skin diseases, examining how developers can generate meaningful evidence, overcome translational challenges and unlock scalable opportunities across underserved patient populations.
With 10+ hours of in-person networking, the summit fosters meaningful collaboration among scientists, clinicians, executives, and decisionmakers working to discover, develop and commercialize the next wave of precision therapeutics.
For organizations committed to shaping the future of inflammatory skin disease drug development, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science, evolving standards of care, and the path to impactful patient outcomes.
Find out more about the 10th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj

9th RNA-Targeted Drug Discovery & Development Summit
2026-11-10 - 2026-11-12 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston, MA, on November 10–12, 2026, as the industry’s only dedicated meeting focused exclusively on RNA-targeted small molecules, bringing together leading minds from biotech, pharma and academia to advance the next generation of RNA-focused therapeutics.
As momentum continues to build across the field, driven by recent clinical progress and increasing investment in RNA-targeted approaches, the summit will explore the latest advances in direct RNA binding, splice modulation, RNA degradation, covalent translation inhibition, epitranscriptomic regulation and condensate biology. Attendees will gain valuable insights into how researchers are overcoming historic challenges in RNA druggability to develop new treatments for oncology, rare genetic diseases and neurodegenerative disorders.
A refreshed 2026 agenda will feature expert-led presentations, case studies, panel discussions and interactive workshops covering functional RNA target selection, structure-guided design, productive chemical space and emerging RNA-targeting technologies. Delegates will also discover practical strategies for improving screening approaches, measuring selectivity, validating targets and accelerating translation from discovery into clinical development.
The summit is expected to welcome 80+ RNA-targeted drug discovery experts and 22+ world-class speakers, including representatives from PTC Therapeutics, AstraZeneca, Sanofi, ReviR Therapeutics, Remix Therapeutics, Arrakis Therapeutics, Dewpoint Therapeutics and Syrna Therapeutics. Through dedicated networking opportunities and collaborative discussions, attendees will connect with the scientists, innovators and decision-makers shaping the future of RNA-targeted medicines.
Whether you are focused on RNA biology, medicinal chemistry, drug discovery, translational research or therapeutic development, this summit offers an unparalleled opportunity to access cutting-edge data, exchange ideas with pioneers in the field and help drive the next wave of innovation in RNA-targeted small molecule therapeutics. As the field continues to mature, the 9th RNA-Targeted Drug Discovery & Development Summit remains the must-attend forum for staying at the forefront of RNA drug discovery.

9th Lab Asset & Facility Management Summit
2026-11-10 - 2026-11-12 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
The 9th Lab Asset & Facility Management (LAFM) Summit 2026 is the leading industry forum dedicated to helping pharmaceutical and biotech organizations optimize lab operations, asset management, facilities, engineering, and research infrastructure. Taking place in Boston, MA from November 10–12, 2026, the flagship event brings together 190+ senior leaders and decision-makers responsible for creating efficient, resilient, and high-performing R&D environments.
As scientific research becomes increasingly complex and organizations face growing pressure to do more with less, LAFM provides a unique platform to explore practical strategies that improve operational efficiency, maximize asset performance, strengthen cross-functional collaboration, and ultimately give scientists more time to focus on breakthrough research.
Join us to gain actionable insights through over 28 real-world case studies, interactive discussions, peer-to-peer benchmarking, and hands-on workshops designed to address the most pressing challenges facing lab operations and facility management teams today. The agenda features dedicated content covering both laboratory operations and site-wide management, helping attendees discover proven approaches to streamlining workflows, improving maintenance strategies, enhancing asset visibility, and building more future-ready research environments.
The 2026 agenda also introduces innovative networking and learning formats, including the LAFM Exchange and the R&D Operations Action Day, giving participants more opportunities to engage with peers, share experiences, and leave with practical frameworks they can implement immediately within their own organizations.
Bringing together experts from leading organizations including Pfizer, Takeda, Novartis, Regeneron, Sanofi, Boehringer Ingelheim, Gilead Sciences, and Eli Lilly, LAFM offers an unrivalled opportunity to connect with the people shaping the future of laboratory and facility operations across the life sciences industry. Whether your goal is to increase operational efficiency, improve facility performance, support scientific teams more effectively, or benchmark your strategy against industry leaders, LAFM is the place to learn, connect, and drive meaningful impact across your organization.
To know more visit: https://ter.li/mnzyk67w

World Cell & Gene Therapy Summit South Korea
2026-11-10 - 2026-11-12 | Grand Hyatt Incheon, 208 Yeongjonghaeannam-ro 321beon-gil, Jung-gu, Incheon, South Korea
South Korea’s cell and gene therapy landscape is highly dynamic, as observed from regulatory approvals, clinical trial progress, and manufacturing activity, from over 150 companies in active drug development. Additionally, with global pharma including Bayer, Novartis and more seeing strategic investments into the CGT space within South Korea, greater opportunities for scientific innovation and technology advancement are yet to come.
The inaugural World Cell & Gene Therapy Summit South Korea is an exclusive opportunity to connect with global pharma and leading Korean biotech showcasing the latest trends in autologous, allogeneic, in vivo, and gene editing therapies to help you identify gaps within your programs and set the roadmap of CGT development in 2026/2027.
One Pass, Two Events: Part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade, this event offers a platform for cross-learning and connections with experts working in RNA and vaccine development and together establish South Korea as a global hub for advanced biopharma innovation.

2nd World RNA-Based Therapeutics & Vaccines Summit South Korea
2026-11-10 - 2026-11-12 | Grand Hyatt Incheon 208 Yeongjonghaeannam-ro, 321 Beon-gil, Yeongjong-gu, 23358, Incheon South Korea
Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest.
Uniquely positioned as the industry’s most comprehensive biopharma forum, the 2nd World RNA-Based Therapeutic & Vaccine Summit South Korea brings together global and local leaders to share first-hand insights into cutting-edge mRNA modalities, delivery technologies, and manufacturing excellence, to progress mRNA medicines to patients faster.
One Pass, Two Events: Part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade, this event offers a platform for cross-learning and connections with experts working in cell and gene therapies and together establish South Korea as a global hub for advanced biopharma innovation.

Biomarker Operations & Biospecimen Management Summit
2026-11-16 - 2026-11-17 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum.
Introducing the inaugural Biomarker Operations & Biospecimen Management Summit, the industry’s first, purpose-built meeting for the heads, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery.
View the newly released agenda: https://ter.li/p9sor70u
With trials growing in complexity, rapidly expanding globally and becoming more data-intensive, biomarker operations has emerged as the critical function for teams looking to advance biomarker- and multi-omics-driven therapies to market.
Answering the industry’s call to unite those collecting, tracking and/or translating biospecimen data, this meeting arrives at a pivotal moment.
You can expect to join 80+ experts to strategize on:

Elevating pre-analytical quality and site collection practices, protecting biomarker signal integrity from the very first draw
Securing and storing biospecimens for the long term, building acquisition, biobanking, and disposition strategies that balance cost, compliance, and future scientific value
Streamlining biosample logistics, kit management and vendor sourcing, cutting waste and tracking errors so every sample reaches the right lab, on time
Navigating consent complexity and evolving regulation, including IVDR and ICH E6(R3), to keep biospecimens compliant and usable for research, long after collection
Embedding FAIR data principles and AI-driven automation into biomarker workflows, replacing manual reconciliation with systems that accelerate decision-making

Alongside this, hear best-in-class strategies from AstraZeneca, Regeneron, Moderna, BioNTech, and Bristol Myers Squibb and real-time updates from Biospecimen Management Consortium (BMC).
Join us in collaboratively building the future playbook that will define the standards for precision medicine therapies.
Registration is complimentary* for qualifying biopharma and researchers. Visit the website to reserve your spot: https://ter.li/6v47cb7t

2nd Model-Informed Drug Development Summit 2026
2026-11-17 - 2026-11-19 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines, reduce risk, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit, taking place November 17-19, 2026, in Boston, MA, brings together senior leaders in pharmacometrics, clinical pharmacology, quantitative sciences, translational medicine, and regulatory science to explore how modelling is transforming decision-making across the entire development lifecycle.
Designed as an intimate and highly interactive forum, this summit moves beyond traditional large-scale industry meetings to provide meaningful peer-to-peer networking, practical case studies, and candid discussions on the real-world challenges of implementing MIDD strategies. Attendees will gain insights from leading organizations including FDA, Health Canada, Sanofi, Eli Lilly, GSK, AbbVie, Novartis, Amgen, Genentech, Gilead Sciences, BMS, Astellas Pharma, Vertex Pharmaceuticals, Johnson & Johnson, and Genmab.
The agenda explores the latest industry developments, including implementation of the finalized ICH M15 guideline, the growing role of quantitative systems pharmacology (QSP), advances in AI-enabled modelling, and the use of real-world evidence to strengthen development decisions. Through case studies, panel discussions, workshops, and roundtable sessions, attendees will learn how to optimize dose selection, improve trial design, accelerate rare disease programs, validate model outputs, demonstrate return on investment from MIDD initiatives, and strengthen regulatory submissions.
In addition to the main conference, dedicated workshops will examine how to integrate pharmacometrics, QSP, machine learning, and AI into connected modelling ecosystems, while also addressing the challenge of building internal and external stakeholder confidence in modelling approaches.
With more than 60 senior industry leaders expected to attend, the summit offers a unique opportunity to benchmark strategies, share best practices, build valuable partnerships, and stay ahead of evolving regulatory and scientific expectations. Whether you are advancing innovative therapies, refining quantitative development strategies, or exploring the future role of AI in drug development, this event provides the practical insights and connections needed to maximize the impact of model-informed approaches across your organization.
To learn more about the event and register online click here.

Novel CNS Biomarkers Summit Europe
2026-11-30 - 2026-12-02 | The Hilton London Olympia, 380 Kensington High St, Kensington, London, W14 8N, United Kingdom
Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging, and digital biomarkers for CNS drug development. Bringing together biomarker, translational medicine, neuroscience, and clinical development leaders, the summit focuses on accelerating the discovery, validation, and implementation of next-generation biomarkers across neurodegenerative and neurological diseases.
As landmark advances in blood-based Alzheimer’s diagnostics, digital biomarkers, multimodal approaches, and precision medicine continue to reshape the field, attendees at the Novel CNS Biomarkers Summit Europe will explore strategies to improve patient stratification, demonstrate target engagement, generate earlier efficacy signals, and de-risk CNS drug development programmes.
Companies attending the Novel CNS Biomarkers Summit Europe:

Roche

UCB

Lundbeck

Servier

NRG Therapeutics

Immunic Therapeutics

Progenra

Saniona

Bial

…and more!
Why attend the Novel CNS Biomarkers Summit Europe?

Join 60+ biomarker and translational medicine leaders

Gain insights from 17+ expert speakers

Explore biomarker strategies across 6+ CNS indications

Participate in interactive workshops and networking opportunities

Discover the brand-new event programme now for more information on sessions and how to register your place.

8th CNS Drug Delivery Summit
2026-12-01 - 2026-12-03 | Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA, 02128, United States
The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system.
Bringing together experts from biopharma, biotech, and academia, the summit will explore the latest advances in drug delivery technologies, including nanoparticles, antibody shuttles, gene therapy vectors, focused ultrasound, and intranasal delivery. Attendees will gain practical insights into improving drug penetration, optimising biodistribution, and advancing therapies for neurological and neurodegenerative diseases.
Through scientific presentations, case studies, and interactive discussions, the event will address key translational, clinical, manufacturing, and regulatory challenges while showcasing innovative approaches that can accelerate CNS drug development.
Join a collaborative community of drug developers, technology innovators, and scientific leaders committed to unlocking the next generation of CNS therapies and improving outcomes for patients worldwide.
Find out more today: https://ter.li/08gi5jio

World CNS Summit South Korea
2026-12-08 - 2026-12-10 | Grand Hyatt Incheon 208 Yeongjonghaeannam-ro, 321 Beon-gil, Yeongjong-gu, 23358, Incheon South Korea
The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted, mechanism-differentiated therapies for neurodegenerative, rare neurodevelopmental, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation, the summit convenes biopharma leaders, translational scientists, and drug developers to explore the next generation of CNS therapeutics and accelerate progress from discovery through early clinical development.
The agenda highlights advances in disease-modifying approaches, blood-brain barrier delivery technologies, RNA-based therapeutics, gene therapies, neuroinflammation, biomarkers, and novel targets beyond traditional amyloid and tau pathways. Attendees will gain insights from leading organizations including ABL Bio, AriBio, Johnson & Johnson, Eli Lilly, Novartis, Takeda, AbbVie, Lundbeck, Angelini Pharma and many more.
Designed to foster meaningful scientific exchange and strategic collaboration, the summit provides a valuable platform to connect with Korean biotech innovators, global pharmaceutical companies, and external innovation leaders evaluating the next wave of CNS opportunities. For decision-makers shaping neuroscience pipelines, partnerships, and licensing strategies, it offers a focused view of the technologies, modalities, and therapeutic approaches driving the future of CNS drug development.
Find out more today: https://ter.li/jrf94t4n
